Scynexis SCYX
NASDAQ SCYX
$5.16 +0.01 (+0.10%)
At close: Aug 20, 2026 · 10:50 AM UTC

Scynexis (SCYX) Net Income towards Common Stockholders (2013 - 2026)

Scynexis' (SCYX) quarterly Net Income towards Common Stockholders came in at -$16.4 million in Q1 2026, down 204.75% YoY from $15.7 million in Q1 2025, and down 234.03% on a QoQ basis from $12.3 million in Q4 2025.

Scynexis (SCYX) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$16.4 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 204.75% year-over-year to -$16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.6 million (up 27.61% YoY) and the FY2025 annual result came in at -$8.6 million, up 59.65% from the prior year.
  • Net Income towards Common Stockholders retreated to -$16.4 million in Q1 2026, from $12.3 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $122.3 million in Q2 2023 to a low of -$33.9 million in Q1 2023.
  • A 5-year average of -$2.9 million and a median of -$6.9 million in 2025 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 4789.92% — and 2023, when it soared 1016.15%.
  • Tracing SCYX's Net Income towards Common Stockholders over 5 years: stood at -$19.5 million in 2022, then decreased by 9.06% to -$21.3 million in 2023, then soared by 78.92% to -$4.5 million in 2024, then soared by 373.49% to $12.3 million in 2025, then slumped by 234.03% to -$16.4 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$16.4 million (Q1 2026), $12.3 million (Q4 2025), and -$8.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 43.81 Bn 42.84 Bn - -
2 Teva Pharmaceutical Industries 43.29 Bn 39.63 Bn 2.15 Bn -576.00 Mn
3 Zoetis 31.59 Bn 29.91 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.67 Bn 22.88 Bn 5.10 Bn 710.19 Mn
5 United Therapeutics 22.24 Bn 19.58 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.79 Bn 17.91 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.71 Bn 15.32 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 12.09 Bn 11.56 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.11 Bn 9.95 Bn - -
10 Scynexis 60.95 Mn -53.74 Mn - -7.09 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -7.09 Mn
Mar 31, 2026 -16.43 Mn
Dec 31, 2025 12.26 Mn
Sep 30, 2025 -8.59 Mn
Jun 30, 2025 -6.89 Mn
Mar 31, 2025 -5.39 Mn
Dec 31, 2024 -4.48 Mn
Sep 30, 2024 -2.81 Mn
Jun 30, 2024 -14.46 Mn
Mar 31, 2024 411,000.00
Dec 31, 2023 -21.27 Mn
Sep 30, 2023 -1.76 Mn
Jun 30, 2023 122.26 Mn
Mar 31, 2023 -33.88 Mn
Dec 31, 2022 -19.50 Mn
Sep 30, 2022 -29.58 Mn
Jun 30, 2022 -13.35 Mn
Mar 31, 2022 -5.45 Mn
Dec 31, 2021 -29.28 Mn
Sep 30, 2021 -605,000.00